The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Through 2030?
The programmed death (pd)-1 non-small cell lung cancer market has experienced substantial growth in recent years. This market is projected to expand from $27.5 billion in 2025 to $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. The expansion observed during the historical period can be attributed to several factors, including the restricted approval of pd-1 inhibitors for nsclc, the increasing prevalence of lung cancer, enhanced physician understanding of immune checkpoint therapies, the conventional reliance on chemotherapy as standard care, and the initial positive outcomes from clinical trials of pembrolizumab and nivolumab.
The programmed death (pd)-1 non-small cell lung cancer market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $41.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from factors such as the creation of innovative combination treatments, the broadening scope of personalized therapies guided by biomarkers, the rising uptake of mRNA vaccine-based interventions, increasing financial commitment to immuno-oncology research, and elevated government and private sector contributions to cancer immunotherapy initiatives. Key trends expected over the forecast horizon encompass a greater embrace of pd-1 monotherapy for nsclc, an increase in combination therapies incorporating chemotherapy, ctla-4 inhibitors, and vegf inhibitors, a surge in investment dedicated to targeted therapy and mrna vaccine research, the broadening of available first-line and second-line treatment choices, and the incorporation of personalized medicine alongside biomarker testing into treatment strategy development.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
Which Drivers Are Advancing The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth?
The programmed death (PD)-1 non-small cell lung cancer market is expected to grow due to the increasing adoption of personalized treatments. These medical approaches involve tailoring therapies to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is fueled by the growing availability of genomic profiling and biomarker testing, which help identify specific mutations and biological markers, allowing clinicians to select therapies more likely to be effective for each individual. Personalized treatments benefit programmed death (PD)-1 non-small cell lung cancer (NSCLC) by customizing therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, in February 2024. Therefore, the increasing adoption of personalized treatments is driving the growth of the programmed death (PD)-1 non-small cell lung cancer market.
What Segment Categories Are Evaluated In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Study?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
What Trends Are Influencing The Future Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Leading companies in the programmed death (PD)-1 non-small cell lung cancer market are concentrating on executing clinical trials for advanced treatments, like monotherapy, to better patient outcomes. Monotherapy represents a therapeutic method that employs a single medicine or treatment to manage a disease or ailment. For example, in March 2025, Akeso, Inc., a biopharmaceutical company based in China, released encouraging data from its Phase III HARMONi-2 trial, which investigated Ivonescimab (AK112) combined with chemotherapy for the first-line management of advanced non-small cell lung cancer (NSCLC). The research fulfilled its primary goal by notably extending progression-free survival in comparison to pembrolizumab, thus emphasizing the therapeutic capability of the dual-targeted bispecific antibody.
Which Key Players Are Active In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Access The Complete Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:
Which Region Accounts For The Highest Share Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company
Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026
Non Small Cell Lung Cancer Nsclc Market Report 2026
Small Cell Lung Cancer Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model